Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.37 |
| ▸ | MAP3K7 | O43318 | 9/20 | 0.36 |
| ▸ | TAB1 | Q15750 | 9/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.35 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.35 |
| ▸ | CHUK | O15111 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3962397 | 0.83 | CYP2A6 (0.53) | AXLCYP2A6IMPDH2KDM4EALDH1A1 | |
| SCHEMBL30940059 | 0.83 | CYP2A6 (0.53) | AXLCYP2A6IMPDH2KDM4EALDH1A1 | |
| SCHEMBL12636082 | 0.78 | CYP2A6 (0.41) | CYP2A6MAP3K7TAB1BRAFKDM4E | |
| SCHEMBL23021840 | 0.77 | CYP2A6 (0.40) | CYP2A6MAP3K7TAB1BRAFKDM4E | |
| SCHEMBL619829 | 0.77 | CYP2A6 (0.43) | AXLCYP2A6IMPDH2MAP3K7TAB1 | |
| SCHEMBL23022152 | 0.77 | CYP2A6 (0.43) | CYP2A6MAP3K7TAB1BRAFKDM4E | |
| SCHEMBL3931535 | 0.77 | CYP2A6 (0.41) | CYP2A6MAP3K7TAB1BRAFKDM4E | |
| SCHEMBL30098534 | 0.77 | CYP2A6 (0.43) | AXLCYP2A6IMPDH2MAP3K7TAB1 | |
| SCHEMBL22303870 | 0.72 | CCR4 (0.38) | CYP2A6MAP3K7TAB1BRAFKDM4E | |
| SCHEMBL20824821 | 0.72 | CYP2A6 (0.37) | CYP2A6MAP3K7TAB1BRAFKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085073-A1 | PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-20250034190-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2025-01-30 | — | — | US | disclosed |
| CN-114341127-B | Aminopyrazine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2024-12-17 | — | — | CN | disclosed |
| US-12122794-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2024-10-22 | — | — | US | disclosed |
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | MIRATI THERAPEUTICS INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | MIRATI THERAPEUTICS INC (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2024059524-A1 | PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-3801499-B1 | INHIBITORS OF SARM1 | DISARM THERAPEUTICS INC (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-4304720-A1 | MTA-COOPERATIVE PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| CN-116903675-A | Organic electroluminescent material and device | 环球展览公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-1879896-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | ABBVIE INC. | 2007-11-01 | — | — | US | disclosed |
| US-20070197536-A1 | phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-08-23 | — | — | US | disclosed |
| CN-1976904-A | Pyridazin-3 (2H) -one derivatives and their use as PDE4 inhibitors | ALMIRALL LAB (ES) | 2007-06-06 | — | — | CN | disclosed |
| EP-1781621-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | Laboratorios Almirall, S.A. (ES) | 2007-05-09 | — | — | EP | disclosed |
| CN-1878759-A | Pyridazin-3 (2H) -one derivatives and their use as PDE4 inhibitors | ALMIRALL PRODESFARMA SA (ES) | 2006-12-13 | — | — | CN | disclosed |
| WO-2006107784-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2006-10-12 | — | — | WO | disclosed |
| EP-1682519-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | Almirall Prodesfarma, S.A. (ES) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005123693-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | LABORATORIOS ALMIRALL, S.A. (ES) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005049581-A1 | PYRIDAZIN-3 (2H) -ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | ALMIRALL PRODESFARMA, S.A. (ES) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197536-A1 | phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease | PDE12, PDE4A, PDE7A | AXL 4583/4885CYP2A6 137/4885IMPDH2 334/4885 |
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | PRMT1, PRMT5, PRMT6 | AXL 4017/4885CYP2A6 4345/4885IMPDH2 351/4885 |
| US-20250034190-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | LIFR, C1R, LBR | AXL 1185/4885CYP2A6 2402/4885IMPDH2 4627/4885 |
| US-20260085073-A1 | PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | MALT1, BCL6, BCL3 | AXL 4612/4885CYP2A6 707/4885IMPDH2 4497/4885 |
| US-12122794-B2 | Organic electroluminescent materials and devices | LIFR, C1R, LBR | AXL 1183/4885CYP2A6 2390/4885IMPDH2 4623/4885 |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | MAP3K20, MAP3K19, MAP4K2 | AXL 708/4885CYP2A6 4150/4885IMPDH2 1656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.